Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

Psyence Group Inc Ordinary Shares Stock News

PSYGFOTC

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$0.3000

Last update: Dec 31, 7:00 PM

Psyence Group Inc Ordinary Shares (PSYGF) Forecast

News

Earnings Psyence Group Inc Ordinary Shares (PSYGF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest Psyence Group Inc Ordinary Shares Stock News | OTC:PSYGF | Benzinga

Get the latest news on Psyence Group Inc Ordinary Shares stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Psyence Group Inc Ordinary Shares performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, January 26, 2024

Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
Lara Goldstein

Tuesday, April 04, 2023

How To Finance A Psychedelics Business? Learn From These Four Companies
Lara Goldstein

Monday, March 27, 2023

Psyched: Australia As Psychedelics Hub, Advanced Scans Of Brain On DMT, New PAC For Congressional Influence, 9 States Advancing Bills & More
Lara Goldstein

Tuesday, March 21, 2023

Psychedelic Research Expands In Australia With Palliative Care Partnership & New MDMA Analog Portfolio
Lara Goldstein

Tuesday, January 24, 2023

Psychedelics Update: MDMA Export, 3D Farm, Recovery Center Reopens, Mushroom Extraction & E-Commerce
Lara Goldstein

Friday, January 20, 2023

Psychedelics Travel: Clinical-Grade Magic Mushrooms Extract Exported From Southern Africa To UK
Lara Goldstein

Tuesday, January 10, 2023

6 Psychedelics Companies Take Action: Here Are The Latest, Major Announcements
Lara Goldstein
Psyence Announced Monday Business Combination between Wholly Owned Subsidiary Psyence Biomed Corp. and Nasdaq listed Newcourt Acquisition Corp
Charles Gross

Tuesday, December 20, 2022

Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
Lara Goldstein

Friday, December 16, 2022

Psyence, Revive Therapeutics Ink Private Placements: Capital To Support Drug Trials
Lara Goldstein

Thursday, December 15, 2022

Psychedelics Company Filament Signs Licensing Deal With Psyence In US, UK And EU
Lara Goldstein

Tuesday, October 11, 2022

European Psychedelics Research Group Nabs $2M In Seed Funding As Clinical Research Picks Up Speed
Lara Goldstein

Thursday, September 29, 2022

International Magic Mushrooms: Where Are They Produced And Where Are They Headed?
Lara Goldstein

Monday, September 26, 2022

Psyched: Magic Mushrooms Vs. Psychotherapy, Psilocybin For Frontline Health Workers & Protecting Peyote
Lara Goldstein

Monday, September 19, 2022

Magic Mushrooms Vs. Psychotherapy For Incurable Cancer Diagnosis Moves Forward In UK Clinical Trials
Lara Goldstein

Monday, April 25, 2022

Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved
Natan Ponieman

Tuesday, April 19, 2022

Psyence, Filament Strike Magic Mushroom Product Licensing Agreement: What You Need To Know
Fermin Orgambide

Connect With Us

About Benzinga

About Us
Careers
Advertise
Contact Us

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Benzinga Pro Trading Platform
Options Trading Strategies and News
Stock Market Trading Ideas and Analysis
Technical Analysis Charts and Indicators
Fundamental Analysis and Valuation
Day Trading Guides and Strategies
Live Investors Events
Pre market Stock Analysis and News
Cryptocurrency Market Analysis and News

Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved